SG10202003996YA - Humanized c5 and c3 animals - Google Patents
Humanized c5 and c3 animalsInfo
- Publication number
- SG10202003996YA SG10202003996YA SG10202003996YA SG10202003996YA SG10202003996YA SG 10202003996Y A SG10202003996Y A SG 10202003996YA SG 10202003996Y A SG10202003996Y A SG 10202003996YA SG 10202003996Y A SG10202003996Y A SG 10202003996YA SG 10202003996Y A SG10202003996Y A SG 10202003996YA
- Authority
- SG
- Singapore
- Prior art keywords
- humanized
- animals
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461988581P | 2014-05-05 | 2014-05-05 | |
US201462067836P | 2014-10-23 | 2014-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202003996YA true SG10202003996YA (en) | 2020-06-29 |
Family
ID=53177902
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202003996YA SG10202003996YA (en) | 2014-05-05 | 2015-05-04 | Humanized c5 and c3 animals |
SG11201608696RA SG11201608696RA (en) | 2014-05-05 | 2015-05-04 | Humanized c5 and c3 animals |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201608696RA SG11201608696RA (en) | 2014-05-05 | 2015-05-04 | Humanized c5 and c3 animals |
Country Status (15)
Country | Link |
---|---|
US (5) | US9795121B2 (en) |
EP (3) | EP4317445A2 (en) |
JP (1) | JP6598798B2 (en) |
KR (1) | KR102461511B1 (en) |
CN (1) | CN106659146B (en) |
AU (1) | AU2015256299C1 (en) |
BR (1) | BR112016025751A2 (en) |
CA (2) | CA3225091A1 (en) |
ES (1) | ES2779070T3 (en) |
IL (1) | IL248481B (en) |
MA (1) | MA51519A (en) |
MX (1) | MX2016014504A (en) |
RU (2) | RU2020103811A (en) |
SG (2) | SG10202003996YA (en) |
WO (1) | WO2015171523A1 (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR095196A1 (en) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | SERUM FREE CELL CULTIVATION MEDIA |
MA51519A (en) | 2014-05-05 | 2020-11-11 | Regeneron Pharma | HUMANIZED C5 AND C3 ANIMALS |
NO2785538T3 (en) | 2014-05-07 | 2018-08-04 | ||
TW202330904A (en) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | Taurine supplemented cell culture medium and methods of use |
WO2017132155A1 (en) * | 2016-01-25 | 2017-08-03 | President And Fellows Of Harvard College | Methods and compositions for detecting and treating schizophrenia |
IL309975A (en) | 2016-06-14 | 2024-03-01 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
US10765762B2 (en) | 2017-02-27 | 2020-09-08 | Regeneron Pharmaceuticals, Inc. | Humanized model of kidney and liver disorders |
BR112020000127A2 (en) | 2017-07-06 | 2020-07-07 | Regeneron Pharmaceuticals, Inc. | method for selecting a soy hydrolyzate, and, glycoprotein |
CN107736281A (en) * | 2017-09-29 | 2018-02-27 | 中国水产科学研究院珠江水产研究所 | A kind of method that pond culture mandarin fish parasite is prevented and treated using probiotics fermention soy sauce residues |
MX2020003589A (en) * | 2017-09-29 | 2020-07-22 | Regeneron Pharma | Non-human animals comprising a humanized. |
JP7242650B2 (en) * | 2017-09-29 | 2023-03-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Non-human animals expressing humanized C1q complexes |
CA3083113A1 (en) | 2017-12-13 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
CN115925882A (en) | 2017-12-22 | 2023-04-07 | 瑞泽恩制药公司 | System and method for characterizing pharmaceutical product impurities |
BR112020013336A2 (en) | 2018-01-31 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | protein pharmaceutical product, methods for characterizing the impurities of the intermediate high molecular weight protein pharmaceutical product, for the production of an antibody, and for characterizing the drug impurities with varying charge, antibody, and system for characterizing high weight drug impurities intermediate molecular. |
TW202311746A (en) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | System and method for characterizing protein dimerization |
AU2019227531A1 (en) | 2018-02-28 | 2020-10-15 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
US11054389B2 (en) | 2018-03-19 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
WO2019195136A1 (en) | 2018-04-03 | 2019-10-10 | Ngm Biopharmaceuticals, Inc. | C3-binding agents and methods of use thereof |
TW202016125A (en) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | Systems and methods for quantifying and modifying protein viscosity |
KR20210031868A (en) | 2018-07-16 | 2021-03-23 | 리제너론 파마슈티칼스 인코포레이티드 | Non-human animal model of DITRA disease and uses thereof |
SG11202011970TA (en) | 2018-08-27 | 2020-12-30 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
TW202024639A (en) | 2018-08-30 | 2020-07-01 | 美商再生元醫藥公司 | Methods for characterizing protein complexes |
AU2020208396A1 (en) | 2019-01-16 | 2021-05-20 | Regeneron Pharmaceuticals, Inc. | Methods for identifying free thiols in proteins |
KR20220004065A (en) | 2019-04-04 | 2022-01-11 | 리제너론 파마슈티칼스 인코포레이티드 | Non-Human Animals Comprising a Humanized Coagulation Factor 12 Locus |
CN114072174A (en) * | 2019-04-24 | 2022-02-18 | 宾夕法尼亚大学理事会 | Dual-function humanized anti-C5 antibody and factor H fusion protein and uses thereof |
WO2020231992A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
JP2022534867A (en) | 2019-06-04 | 2022-08-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Non-human animals containing humanized TTR loci with beta slip mutations and methods of use |
EP3796776A1 (en) | 2019-06-07 | 2021-03-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized albumin locus |
CA3150234C (en) | 2019-09-24 | 2023-12-12 | Robert Stairs | Systems and methods for chromatography use and regeneration |
EP4065086A1 (en) | 2019-11-25 | 2022-10-05 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
MX2022008973A (en) | 2020-01-21 | 2022-08-11 | Regeneron Pharma | Deglycosylation methods for electrophoresis of glycosylated proteins. |
WO2022047108A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
AU2021352420A1 (en) | 2020-10-01 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Rodent animals expressing human cr1 |
JP2023551446A (en) | 2020-11-25 | 2023-12-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Sustained release formulation using non-aqueous film emulsification |
EP4262757A1 (en) | 2020-12-17 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
KR20230134117A (en) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | Methods for improving protein titer in cell culture |
KR20230150300A (en) | 2021-03-03 | 2023-10-30 | 리제너론 파마슈티칼스 인코포레이티드 | Systems and methods for quantifying and altering protein viscosity |
BR112023018665A2 (en) | 2021-03-26 | 2023-10-03 | Regeneron Pharma | METHODS AND SYSTEMS FOR DEVELOPING MIXING PROTOCOLS |
AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
AR127006A1 (en) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | A HIGH-PERFORMANCE, MASS SPECTROMETRY-BASED METHOD FOR QUANTIFYING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
AU2022359898A1 (en) | 2021-10-07 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
TW202323817A (en) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Systems and methods of ph modeling and control |
US20230129265A1 (en) | 2021-10-26 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
WO2023077053A2 (en) | 2021-10-28 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
WO2023177836A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
EP0138854B1 (en) | 1983-03-08 | 1992-11-04 | Chiron Mimotopes Pty. Ltd. | Antigenically active amino acid sequences |
DE3590766C2 (en) | 1985-03-30 | 1991-01-10 | Marc Genf/Geneve Ch Ballivet | |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
DE3883899T3 (en) | 1987-03-18 | 1999-04-22 | Sb2 Inc | CHANGED ANTIBODIES. |
US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
DE69130831T2 (en) | 1990-11-21 | 1999-09-16 | Iterex Pharma Lp | SYNTHESIS OF EQUIMOLAR MIXTURES OF VARIOUS OLIGOMERS, SPECIALLY OLIGOPEPTIDE MIXTURES |
DE69129154T2 (en) | 1990-12-03 | 1998-08-20 | Genentech Inc | METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5644048A (en) | 1992-01-10 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Process for preparing phosphorothioate oligonucleotides |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US6166288A (en) * | 1995-09-27 | 2000-12-26 | Nextran Inc. | Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor |
GB9521943D0 (en) | 1995-10-26 | 1996-01-03 | Univ Hertfordshire | Coded particles for process sequence tracking in combinatorial compound library preparation |
DE69937291T2 (en) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | ANTIBODY VARIANTS AND FRAGMENTS THEREOF |
US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
US6280946B2 (en) | 1998-08-07 | 2001-08-28 | Boston Probes, Inc. | PNA probes, probe sets, methods and kits pertaining to the universal detection of bacteria and eucarya |
EP1141708A1 (en) | 1998-12-28 | 2001-10-10 | Sunesis Pharmaceuticals Inc. | Identifying small organic molecule ligands for binding |
EP1701611B1 (en) * | 2003-12-24 | 2011-05-18 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
PT1713503E (en) | 2004-02-10 | 2013-11-14 | Nat Jewish Health | Inhibition of factor b, the alternative complement pathway and methods related thereto |
JP5252922B2 (en) | 2004-10-19 | 2013-07-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Methods for generating homozygous animals for genetic modification |
JP2009523237A (en) | 2006-01-11 | 2009-06-18 | ノヴォ ノルディスク アクティーゼルスカブ | Improved spherical coded beads |
MX2010009190A (en) * | 2008-02-20 | 2010-09-10 | G2 Inflammation Pty Ltd | HUMANIZED ANTI-C5aR ANTIBODIES. |
RU2425880C2 (en) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Method of producing transgene mice |
AU2010303737B2 (en) | 2009-10-06 | 2014-05-29 | Institute For Research In Biomedicine (Irb) | Genetically modified mice and engraftment |
RU2730643C2 (en) | 2011-02-15 | 2020-08-24 | Ридженерон Фармасьютикалз, Инк. | Humanised m-csf mice |
RS55949B1 (en) | 2011-10-28 | 2017-09-29 | Regeneron Pharmaeuticals Inc | Humanized il-6 and il-6 receptor |
DK3262932T3 (en) | 2011-10-28 | 2019-08-05 | Regeneron Pharma | Genetically modified mice with major histocompatibility complex |
US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
NZ741951A (en) | 2012-09-07 | 2020-04-24 | Institute For Res In Biomedicine Irb | Genetically modified non-human animals and methods of use thereof |
CN114766432A (en) | 2012-11-05 | 2022-07-22 | 再生元制药公司 | Genetically modified non-human animals and methods of use thereof |
LT2958937T (en) | 2013-02-22 | 2018-11-26 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
US9155290B2 (en) | 2013-10-15 | 2015-10-13 | Regeneron Pharmaceuticals, Inc. | Humanized IL-15 animals |
EP3071025B1 (en) | 2013-11-19 | 2018-10-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
MA51519A (en) | 2014-05-05 | 2020-11-11 | Regeneron Pharma | HUMANIZED C5 AND C3 ANIMALS |
-
2015
- 2015-05-04 MA MA051519A patent/MA51519A/en unknown
- 2015-05-04 RU RU2020103811A patent/RU2020103811A/en unknown
- 2015-05-04 EP EP23202404.2A patent/EP4317445A2/en active Pending
- 2015-05-04 BR BR112016025751A patent/BR112016025751A2/en not_active Application Discontinuation
- 2015-05-04 MX MX2016014504A patent/MX2016014504A/en active IP Right Grant
- 2015-05-04 EP EP19211905.5A patent/EP3636073B1/en active Active
- 2015-05-04 JP JP2016566228A patent/JP6598798B2/en active Active
- 2015-05-04 ES ES15722639T patent/ES2779070T3/en active Active
- 2015-05-04 US US14/703,818 patent/US9795121B2/en active Active
- 2015-05-04 KR KR1020167032659A patent/KR102461511B1/en active IP Right Grant
- 2015-05-04 EP EP15722639.0A patent/EP3142483B1/en active Active
- 2015-05-04 CN CN201580034127.8A patent/CN106659146B/en active Active
- 2015-05-04 RU RU2016146390A patent/RU2713327C2/en active
- 2015-05-04 SG SG10202003996YA patent/SG10202003996YA/en unknown
- 2015-05-04 CA CA3225091A patent/CA3225091A1/en active Pending
- 2015-05-04 WO PCT/US2015/029111 patent/WO2015171523A1/en active Application Filing
- 2015-05-04 AU AU2015256299A patent/AU2015256299C1/en active Active
- 2015-05-04 CA CA2946412A patent/CA2946412C/en active Active
- 2015-05-04 SG SG11201608696RA patent/SG11201608696RA/en unknown
-
2016
- 2016-10-25 IL IL248481A patent/IL248481B/en active IP Right Grant
-
2017
- 2017-07-26 US US15/660,833 patent/US10492477B2/en active Active
-
2018
- 2018-07-02 US US16/025,377 patent/US10524458B2/en active Active
-
2019
- 2019-10-21 US US16/658,541 patent/US11178860B2/en active Active
-
2021
- 2021-10-20 US US17/505,834 patent/US20220132818A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL248481B (en) | Humanized c5 and c3 animals | |
IL304841A (en) | Humanized il-4 and il-4r animals | |
IL251537A0 (en) | Humanized anti-ox40 antibodies and uses thereof | |
IL250461A0 (en) | Anti-cll-1 antibodies and immunoconjugates | |
IL249188A0 (en) | Anti-her2 glycoantibodies and uses thereof | |
IL252216A0 (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
IL284291A (en) | Humanized anti-acth antibodies and use thereof | |
FI3215147T3 (en) | Neuro-attenuating norketamine compounds and methods | |
AP2017009805A0 (en) | Fish trap | |
PT3101131T (en) | Anti-transthyretin humanized antibody | |
IL251837A0 (en) | Anti-endoglin antibodies and uses thereof | |
PT3101132T (en) | Anti-transthyretin human antibody | |
PL3180356T3 (en) | Human anti-fgfr4 antibody | |
ZA201702491B (en) | Optimized braid construction | |
HK1243342A1 (en) | Compounds and methods | |
PL2905411T3 (en) | Gate | |
GB201415250D0 (en) | Compound and method | |
EP3185901C0 (en) | Compound and method | |
GB201409990D0 (en) | Loungers for pets | |
GB201421735D0 (en) | Humanized gut microbiota | |
GB201420773D0 (en) | Compound and method | |
GB201415247D0 (en) | Compound and method | |
GB201415254D0 (en) | Compound and method | |
GB201406597D0 (en) | Compound and method | |
GB201406596D0 (en) | Compound and method |